ARDS Stock Overview
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aridis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.065 |
| 52 Week High | US$0.54 |
| 52 Week Low | US$0.05 |
| Beta | 1.04 |
| 1 Month Change | -12.28% |
| 3 Month Change | -13.95% |
| 1 Year Change | -65.63% |
| 3 Year Change | -98.96% |
| 5 Year Change | -99.37% |
| Change since IPO | -99.50% |
Recent News & Updates
Recent updates
Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%
Sep 26Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M
Aug 16Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?
Feb 17
Aridis Pharmaceuticals EPS misses by $0.02
Nov 20Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| ARDS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 0.4% | 1.0% |
| 1Y | -65.6% | 0.9% | 21.9% |
Return vs Industry: ARDS underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: ARDS underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ARDS volatility | |
|---|---|
| ARDS Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARDS's share price has been volatile over the past 3 months.
Volatility Over Time: ARDS's weekly volatility has decreased from 26% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 37 | Vu Truong | www.aridispharma.com |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11.
Aridis Pharmaceuticals, Inc. Fundamentals Summary
| ARDS fundamental statistics | |
|---|---|
| Market cap | US$3.12m |
| Earnings (TTM) | -US$1.14m |
| Revenue (TTM) | US$22.36m |
0.1x
P/S Ratio-2.7x
P/E RatioIs ARDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARDS income statement (TTM) | |
|---|---|
| Revenue | US$22.36m |
| Cost of Revenue | US$17.15m |
| Gross Profit | US$5.21m |
| Other Expenses | US$6.35m |
| Earnings | -US$1.14m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 23.28% |
| Net Profit Margin | -5.11% |
| Debt/Equity Ratio | -28.9% |
How did ARDS perform over the long term?
See historical performance and comparison